Biotech

Biotech Capital Markets in 2026: Back to Basics, Built to Last

.

Wockhardt targets 50% of revenue from novel drugs within five years

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

MedTherapy bets on low-cost CAR-T manufacturing with Noida CDMO push

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

Claire has what it takes to lead Biocon forward: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase

Piramal Pharma bets on FY27 rebound; expects mid-teens growth, margin gains

Piramal Pharma expects a recovery in FY27 with mid-teens revenue growth and improved margins, supported by CDMO rebound, stronger order inflows, and global supply chain shifts

India needs to rethink IPO norms for biotech startups: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw urges IPO reforms, saying India's listing norms hinder biotech firms that need long R&D cycles before generating revenue

India's bioeconomy to hit $300 bn by 2033 on innovation demand: Report

Report flags global patent cliff and rising R&D costs as catalysts, with India emerging as a cost-efficient hub backed by policy support, faster trials and expanding biotech ecosystem

Miltenyi Biotec weighs local CGT manufacturing, eyes export potential

German biotech firm explores hospital-linked cell and gene therapy manufacturing in India while assessing long-term opportunities in regional CGT production, training and exports

Biotech sovereignty in AI is key to India's health security: Biocon's Shaw

India AI Impact Summit 2026: Kiran Mazumdar-Shaw said India must build biotech sovereignty powered by AI to protect health security and lead the future of medicine

Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth

Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E

How China's biotech research boom is sending lab monkey prices higher

With a record wave of deal-making, IPO activity and fresh venture capital flowing into Chinese biotech in 2024-25, prices of lab monkeys used for drug testing are rising again

Supreme Court's Sterling ruling may pave way for similar settlements

SC's decision to close criminal proceedings against the Sandesara brothers after a substantial repayment has raised concerns that other high-profile economic offenders may seek similar settlements

Must target biotech sovereignty by 2047: Biocon's Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw urges India to achieve 'biotech sovereignty' by 2047, driven by a $330 bn bioeconomy, BioE3 framework, scale exports, a sovereign AI stack, and crucial R&D investment

Biocon arm Syngene eyes late-stage clinical supplies amid regulatory shift

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth

In-space industry set to unlock multi-billion dollar mkt in manufacturing

In-space manufacturing uses the near-weightless environment of space to produce materials and products of superior quality

China's biotech surge shifts global drug innovation, stirs US tension

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough designations as they gain confidence in China's biotech innovation

Utopia secures $1.5 mn from Whale Tank to develop obesity vaccine

Hyderabad-based biotech Utopia Therapeutics raises seed funding from Whale Tank to accelerate preclinical work on its novel immunotherapy vaccine targeting obesity

Eli Lilly to acquire gene-editing firm Verve Therapeutics for $1.3 billion

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its blockbuster weight-loss and diabetes drugs

Telangana govt bags ₹2,150 cr investment in biotech, tech, fintech sectors

The investment is expected to promote innovation and growth, further positioning Telangana as a global hub for emerging industries